Latest Conference Articles

Endo 2017: Men’s Health

Endo 2017: Men’s Health

April 4th 2017

ENDO

Men’s health studies presented at ENDO 2017 included a possible prostate cancer treatment and the potential of hormone therapy to prevent frailty.

Can We Suppress Sugar Cravings?

Can We Suppress Sugar Cravings?

April 3rd 2017

ENDO

Researchers sought to discover the specific physiological pathways of fibroblast growth factor 21.

Clinical Dilemmas in Diabetes

Clinical Dilemmas in Diabetes

April 3rd 2017

ENDO

Research presented at ENDO 2017 explored options to reduce complications in patients with diabetes and microalbuminuria and patients with cystic fibrosis.

Role of the Striatum in Obesity

Role of the Striatum in Obesity

April 2nd 2017

ENDO

Researchers investigated possible differences in the function of the striatum both before and after the development of obesity.

ENDO 2017: Sleep Studies

ENDO 2017: Sleep Studies

April 2nd 2017

ENDO

Studies presented at ENDO 2017 examined the impact of sleep disorders on gestational diabetes, bone formation, and adolescents with and without diabetes.

ENDO 2017: Top Sessions

ENDO 2017: Top Sessions

March 31st 2017

ENDO

You won’t want to miss these top sessions and new features at this year’s Endocrinology Society’s annual meeting, April 1-4, in Orlando, FL.

Physical Activity Impacts Diabetes Prevention

Physical Activity Impacts Diabetes Prevention

July 20th 2016

ADA

Follow-up data from the landmark Diabetes Prevention Study examined the role of physical activity in diabetes prevention.

Understanding SGLT2 Inhibitors

Understanding SGLT2 Inhibitors

July 12th 2016

ADA

This slideshow highlights several studies regarding the effects of SGLT2 inhibitors, which were presented at the 2016 ADA Scientific Sessions.

Beyond Basal Insulin in Type 2 Diabetes

Beyond Basal Insulin in Type 2 Diabetes

July 1st 2016

ADA

Several studies presented at ADA 2016 discussed going beyond basal insulin treatments for patients with type 2 diabetes.

IRIS Trial Examines CV and Diabetes Risks

IRIS Trial Examines CV and Diabetes Risks

June 16th 2016

ADA

A secondary analysis of data from the Insulin Resistance Intervention after Stroke trial (IRIS) examined pioglitazone’s effect on diabetes prevention.